Avalo Therapeutics, Inc. (AVTX) Financials

$9.02

$0.07 (0.78%)
Last update: 04:00 PM EST
Day's range
$8.8
Day's range
$9.8
$20M$20M$0$0-$20M-$20M-$40M-$40M-$60M-$60M-$80M-$80M-$100M-$100MEarning201820182019201920202020202120212022202220232023202420240%0%-2000%-2000%-4000%-4000%-6000%-6000%-8000%-8000%-10000%-10000%-12000%-12000%Profit Margin
Profit Margin
Revenue
Earnings

AVTX Income statement / Annual

Last year (2024), Avalo Therapeutics, Inc.'s total revenue was $441.00 K, a decrease of 77.08% from the previous year. In 2024, Avalo Therapeutics, Inc.'s net income was -$35.13 M. See Avalo Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Operating Revenue $441.00 K $1.92 M $18.05 M $5.40 M $6.70 M $6.75 M $18.33 M $27.81 M $1.15 M $0.00
Cost of Revenue -$366.00 K $1.28 M $3.43 M $1.49 M $300.00 K $11.63 M $7.48 M $635.65 K $8.24 M $23.51 K
Gross Profit $807.00 K $640.00 K $14.62 M $3.91 M $6.40 M -$4.88 M $10.85 M $27.18 M -$7.09 M -$23.51 K
Gross Profit Ratio 1.83 0.33 0.81 0.72 0.96 -0.72 0.59 0.98 -6.15 0
Research and Development Expenses $52.08 M $13.78 M $31.31 M $59.84 M $32.19 M $11.76 M $5.79 M $4.37 M $10.15 M $6.59 M
General & Administrative Expenses $16.45 M $10.27 M $20.64 M $21.83 M $17.42 M $10.12 M $10.68 M $7.94 M $7.08 M $4.42 M
Selling & Marketing Expenses $789.00 K $33.00 K $76.00 K $2.83 M $2.34 M $1.48 M $8.52 M $973.35 K $0.00 $0.00
Selling, General & Administrative Expenses $17.24 M $10.30 M $20.71 M $24.66 M $19.76 M $11.61 M $19.20 M $8.91 M $7.08 M $4.42 M
Other Expenses $0.00 $3.91 M $38.00 K $1.55 M $1.74 M $1.34 M $13.66 K $0.00 $0.00 $0.00
Operating Expenses $69.32 M $27.99 M $52.06 M $86.04 M $53.69 M $24.71 M $29.52 M $13.29 M $17.23 M $11.01 M
Cost And Expenses $68.95 M $29.28 M $55.49 M $87.53 M $53.99 M $24.14 M $37.00 M $13.92 M $17.23 M $11.01 M
Interest Income $0.00 $0.00 $0.00 $0.00 $49.00 K $121.33 K $0.00 $0.00 $0.00 $0.00
Interest Expense $0.00 $3.42 M $4.17 M $2.39 M $0.00 $0.00 $0.00 $0.00 $0.00 $793.21 K
Depreciation & Amortization $169.00 K $158.00 K $166.00 K $1.66 M $1.84 M $1.46 M $1.85 M $425.48 K $26.86 K $23.51 K
EBITDA -$68.34 M -$23.29 M -$37.29 M -$80.50 M -$45.45 M -$17.36 M -$13.07 M $14.35 M -$16.05 M -$10.46 M
EBITDA Ratio -154.97 -12.1 -2.07 -14.91 -6.78 -2.57 -0.71 0.52 -13.92 0
Operating Income Ratio -155.36 -14.22 -2.07 -15.22 -4.02 -2.58 -2.15 0.5 -13.95 0
Total Other Income/Expenses Net $33.50 M -$4.18 M -$4.19 M -$2.41 M $5.67 M $12.26 M $54.93 K -$53.64 K -$391.56 K $519.84 K
Income Before Tax -$35.02 M -$31.53 M -$41.63 M -$84.55 M -$67.18 M -$15.99 M -$40.09 M $13.84 M -$16.47 M -$10.49 M
Income Before Tax Ratio -79.4 -16.39 -2.31 -15.66 -10.03 -2.37 -2.19 0.5 -14.29 0
Income Tax Expense $114.00 K $14.00 K $28.00 K -$196.00 K -$2.79 M $280.00 K -$33.91 K $1.97 M $364.14 K -$543.51 K
Net Income -$35.13 M -$31.54 M -$41.66 M -$84.35 M -$64.38 M -$16.27 M -$40.05 M $11.87 M -$16.47 M -$10.49 M
Net Income Ratio -79.66 -16.4 -2.31 -15.63 -9.61 -2.41 -2.19 0.43 -14.29 0
EPS -4.32 -113.58 -1062.65 -2330.66 -2523.77 -819.74 -3317.28 1856.88 -21.93 -16.21
EPS Diluted -3.26 -113.58 -1062.65 -2330.66 -2523.77 -819.74 -3317.28 1822.74 -21.93 -16.21
Weighted Average Shares Out $8.13 M $277.73 K $39.20 K $36.19 K $25.51 K $19.85 K $12.07 K $6.39 K $3.07 K $772.92
Weighted Average Shares Out Diluted $10.78 M $277.73 K $39.20 K $36.19 K $25.51 K $19.85 K $12.07 K $6.51 K $3.07 K $772.92
Link